AdimrSC-2f / Adimmune - LARVOL DELTA

Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - P1/2 | N=241 | Completed | Sponsor: Adimmune Corporation | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - P1/2 | N=240 | Active, not recruiting | Sponsor: Adimmune Corporation | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: Adimmune Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine (clinicaltrials.gov) - P1 | N=68 | Completed | Sponsor: Adimmune Corporation | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Dose-finding Study for AdimrSC-2f Vaccine (clinicaltrials.gov) - P1/2; N=240; Not yet recruiting; Sponsor: Adimmune Corporation

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine (clinicaltrials.gov) - P1; N=70; Active, not recruiting; Sponsor: Adimmune Corporation; Recruiting ➔ Active, not recruiting; Trial completion date: Jul 2021 ➔ Oct 2021

Clinical • Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Adimmune Corporation; Trial completion date: Mar 2021 ➔ Jul 2021

Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

CORONAVIRUS/Taiwan's COVID vaccines about to enter phase 2 clinical trials: FDA (Focus Taiwan) - P1, N=NA; "A number of COVID-19 vaccines developed in Taiwan have completed the first phase of clinical trials and are likely to enter phase 2 trials by the end of the year...The developers of the vaccines are currently compiling the data from the first-phase trials and are preparing to start the second phase of their vaccine trials in late December...The individuals who participated in the clinical trials...did not report any major side effects in the seven days after they were vaccinated...The companies will be eligible to each receive a maximum NT$300 million (US$10.6 million) in additional government funding if they enroll their first participant in the second phase of their clinical trials by Dec. 31, and up to NT$240 million if they miss that deadline but enroll their first participant by Jan. 31, 2021..."

Financing • New P2 trial • P1 data • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate the Safety and Immunogenicity of AdimrSC-2f Vaccine (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Adimmune Corporation

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease